Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome.
性状
Solid
体外研究(In Vitro)
Lanreotide (BIM 23014) (100? nM; 0-48 h) enhanced radiation-induced apoptosis.Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57?nM.Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Lanreotide acetate (2.5-10mg/kg; s.c.; daily for 5 days) resluts in tumor growth inhibition. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Male nude mice, 8 weeks old and 20–25?g in
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisture and light, under nitrogenPowder -80°C 2 years;-20°C 1 ye
[1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55.[2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 J
溶解度数据
In Vitro: DMSO : 100 mg/mL (86.48 mM; Need ultrasonic)H2O : 25 mg/mL (21.62 mM; Need ultrasonic)配制储备液